Thought Leadership
At NDA our experts stay abreast with the evolving environment and the new regulatory requirements that it gives rise to. One of the results of these activities is a stream of articles, commentaries and white papers that we publish for the benefit of our clients and followers. It captures the state of the art of our industry today.
We call it Thought Leadership.
Articles and White Papers
Service:
Scientific:
Sort by:
All services
Development Strategy
Medical Devices
Pharmacovigilance
NDA Advisory Board
Strategic Communications
Regulatory
Quality & Compliance
All expertise
Oncology
Vaccine
Immunogenicity
HTA
In-Vitro Diagnostics
Non-Clinical
Cell and Gene Therapy
Biostatistics
Cardiology
ATMP
Rare Disease
Market Access
CMC
Clinical
Paediatric
Acceleration Strategies
Medical Devices
Quality
Patient Safety
23-09-2020
Integrated product development for ATMPs
In this article, published in the September issue of MedNous, Claes and Paula discuss why an integrated product development strategy for ATMPs is essential to meet both regulatory and HTA requirements.
01-09-2020
Market access for immune-oncology products in the EU
In this article, published in Volume 22 September 2020 of Pharmafocus, Claes Buxfeldt discusses key considerations in early development to succeed with market access for immune-oncology products in the EU.
02-05-2020
Enhancing Pharmacovigilance
This article discusses the tremendous expansion in oncology products with great opportunities that will benefit patients.
02-04-2020
New EU In vitro Diagnostics Regulation (IVDR) and Companion Diagnostics
The companion diagnostics market is an emerging market and is anticipated to experience significant growth owing to increase in targeted therapies, rise in demand for personalised medicine with increase in awareness in emerging economies, discovery of n...
02-01-2020
Hopes and challenges in the future of the immuno-oncology field
There is no doubt that the area of oncology development has exploded in the last few years.
02-08-2018
CAR T-Cells for Cancer Immunotherapy – Moving Target for Industry?
This article discusses the product-and patient-related variables that may pose challenges for the industry and developers both from the scientific and regulatory perspective.